Our previous data indicate that IL-6 facilitates LH2 expression in breast cancer, and a high expression of LH2 in breast cancer leads to epithelial–mesenchymal transition (EMT) and poor prognosis (He et al., 2018). This evidence concerns the gene IL6 and breast carcinoma.